A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer
Hoffmann-La Roche
Hoffmann-La Roche
Pfizer
Astellas Pharma Inc
Merck Sharp & Dohme LLC
Incyte Corporation
Akeso
DualityBio Inc.
AstraZeneca
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
Arcus Biosciences, Inc.
Arcus Biosciences, Inc.
UNICANCER
UNC Lineberger Comprehensive Cancer Center
Novartis
AstraZeneca
AstraZeneca
Genentech, Inc.
Gilead Sciences
AstraZeneca
National Health Research Institutes, Taiwan
M.D. Anderson Cancer Center
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Queen Mary University of London
Washington University School of Medicine
M.D. Anderson Cancer Center
ImmunityBio, Inc.
Revolution Medicines, Inc.
University Health Network, Toronto
Memorial Sloan Kettering Cancer Center
Abramson Cancer Center at Penn Medicine
Agenus Inc.
Merck Sharp & Dohme LLC
University of Southern California
Thomas Jefferson University
Eli Lilly and Company
Bristol-Myers Squibb
ImmunityBio, Inc.
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Daiichi Sankyo
Gilead Sciences
Merck Sharp & Dohme LLC
Gilead Sciences
Verastem, Inc.
AbbVie
Fudan University
City of Hope Medical Center
University of Cincinnati